Latham Reps Cancer Biotech's Upsized $231M IPO
Guided by Latham & Watkins, oncology-focused biotechnology firm Revolution Medicines announced plans Tuesday to significantly increase the size of its planned initial public offering to $231 million at midpoint, a nearly...To view the full article, register now.
Already a subscriber? Click here to view full article